U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07053319) titled 'SGLT2i, Pioglitazone, and Ketone Production in T2D' on June 26.
Brief Summary: To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).
Study Start Date: Feb. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes
Intervention:
DRUG: Empagliflozin 25 MG plus Pioglitazone placebo
A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
DRUG: Pioglitazone 15 mg increased to 30 mg af...